Pancreatic cancer is the fourth leading cause of cancer mortality. The gastrointestinal hormone, gastrin, stimulates human pancreatic cancer growth via its receptor, CCKBR, and a splice-variant of CCKBR (termed CCKCR) detected only in cancer cells. This cancer-associated variant retains the fourth intron and exhibits increased cell signaling. Recently, a single nucleotide polymorphism (SNP; C\u3eA) in the fourth intron was identified. Presence of SNP(A) was correlated with CCKCR protein expression in pancreatic cancer specimens and decreased patient survival. We hypothesize expression of human CCKCR in murine pancreatic cancer cells will increase tumor growth and metastasis relative to expression of human CCKBR. The aim of this study was to...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death worldwid...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death worldwid...
AIM: To investigate the effects of gastrin and cholecystokinin (CCK) and their specific antagonists ...
Currently, the five-year survival rate of pancreatic cancer is an abysmal 5%. Our lab has focused on...
Abstract Background Two main types of receptors for gastrin and cholecystokinin (CCK) have been clon...
There currently are no tests available for early diagnosis or for the identification of patients at ...
Pancreatic cancer is aggressive and poorly understood with a five-year survival rate of only 9% beca...
Cholecystokinin (CCK) and gastrin stimulate growth of pancreatic cancer. Although down-regulation of...
AIM: To investigate the effects of gastrin and cholecystokinin (CCK) and their specific antagonists ...
The wild-type cholecystokinin type 2 (CCK(2)) receptor is expressed in many gastrointestinal and lun...
The gastrointestinal (GI) hormone, gastrin, promotes cancer progression and its down-regulation has ...
Problem: The expression of the human cholecystokinin-B/gastrin receptor has been reported in human c...
Pancreatic cancer is an extremely aggressive cancer with a five-year survival rate of less than 6%, ...
Pancreatic cancer is an extremely aggressive cancer with a five-year survival rate of less than 6%, ...
OBJECTIVES: This study evaluated the effects of gastrin messenger RNA (mRNA) down-regulation on grow...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death worldwid...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death worldwid...
AIM: To investigate the effects of gastrin and cholecystokinin (CCK) and their specific antagonists ...
Currently, the five-year survival rate of pancreatic cancer is an abysmal 5%. Our lab has focused on...
Abstract Background Two main types of receptors for gastrin and cholecystokinin (CCK) have been clon...
There currently are no tests available for early diagnosis or for the identification of patients at ...
Pancreatic cancer is aggressive and poorly understood with a five-year survival rate of only 9% beca...
Cholecystokinin (CCK) and gastrin stimulate growth of pancreatic cancer. Although down-regulation of...
AIM: To investigate the effects of gastrin and cholecystokinin (CCK) and their specific antagonists ...
The wild-type cholecystokinin type 2 (CCK(2)) receptor is expressed in many gastrointestinal and lun...
The gastrointestinal (GI) hormone, gastrin, promotes cancer progression and its down-regulation has ...
Problem: The expression of the human cholecystokinin-B/gastrin receptor has been reported in human c...
Pancreatic cancer is an extremely aggressive cancer with a five-year survival rate of less than 6%, ...
Pancreatic cancer is an extremely aggressive cancer with a five-year survival rate of less than 6%, ...
OBJECTIVES: This study evaluated the effects of gastrin messenger RNA (mRNA) down-regulation on grow...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death worldwid...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death worldwid...
AIM: To investigate the effects of gastrin and cholecystokinin (CCK) and their specific antagonists ...